Eslicarbazepine acetate : its effectiveness as adjunctive therapy in clinical trials and open studies by Shorvon, SD et al.
REVIEW
Eslicarbazepine acetate: its effectiveness as adjunctive therapy
in clinical trials and open studies
S. D. Shorvon1 • E. Trinka2,8 • B. J. Steinhoff3 • M. Holtkamp4 • V. Villanueva5 •
J. Peltola6 • E. Ben-Menachem7
Received: 4 October 2016 / Accepted: 8 November 2016 / Published online: 18 January 2017
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Eslicarbazepine acetate (ESL) is a once-daily
antiepileptic drug that is approved as adjunctive therapy in
adults with focal-onset seizures. Following oral adminis-
tration, ESL is rapidly metabolized to its active metabolite,
eslicarbazepine, which acts primarily by enhancing slow
inactivation of voltage-gated sodium channels. The effi-
cacy and safety/tolerability of ESL in the adjunctive setting
were established in a comprehensive Phase III program
(n = 1702 randomized patients) and this evidence has been
supported by several open studies (n = 864). ESL treat-
ment has demonstrated improvements in health-related
quality of life, in both randomized clinical trials and open
studies. ESL has also been shown to be usually well tol-
erated and efficacious when used in the adjunctive setting
in elderly patients. The effectiveness of ESL as the only
add-on to antiepileptic drug monotherapy has been
demonstrated in a multinational study (n = 219), subgroup
analyses of which have also shown it to be efficacious and
generally well tolerated in patients who had previously not
responded to carbamazepine therapy. Open studies have
also demonstrated improvements in tolerability in patients
switched overnight from oxcarbazepine to ESL. Due to
differences in pharmacokinetics, pharmacodynamics, and
metabolism, there may be clinical situations in which it is
appropriate to consider switching patients from oxcar-
bazepine or carbamazepine to ESL.
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Introduction
Eslicarbazepine acetate (ESL) is a once-daily (OD)
antiepileptic drug (AED) that is approved in Europe as
adjunctive therapy in adults with focal-onset seizures, with
or without secondary generalization [1], and, in the USA,
for the treatment of focal-onset seizures as monotherapy or
adjunctive therapy [2]. The efficacy and safety/tolerability
of ESL as adjunctive therapy for focal-onset seizures in
adults have been established in several randomized, dou-
ble-blind, placebo-controlled, Phase III trials [3–6] and
long-term extension studies [7–9]. In addition, an open-
label, non-controlled Phase III trial has assessed the safety
and efficacy of adjunctive ESL treatment in elderly patients
(aged C65 years) [10].
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Controlled clinical trials are essential in the licensing
process of a new AED, but they typically employ strict
inclusion/exclusion criteria and rigid dosing and titration
schedules; whereas, in everyday clinical practice, patients
are more diverse in terms of clinical characteristics, such as
age, comorbidities and comedications, and treatment is
individualized to each patient’s needs [11, 12]. ‘Real-
world’ open studies are, therefore, required to complement
evidence from clinical trials, by determining how the
efficacy of an agent translates into effectiveness in clinical
practice and by providing pragmatic guidance on optimal
dosing and titration schedules. An aspect of determining
the effectiveness of a treatment is to assess its impact on
patients’ quality of life (QoL). This is particularly impor-
tant for chronic conditions, such as epilepsy, where the
effectiveness of treatment relies first and foremost on the
patient’s willingness and ability to be compliant with the
treatment over the long term. Since its approval, ESL’s
safety and effectiveness have been investigated in open,
unblinded studies [13–17], and its effects on QoL have
been investigated in both the clinical trial setting and open
studies [7, 8, 13, 18].
The aims of this article were to provide a brief overview
of ESL’s pharmacology and to review current clinical
evidence for ESL as an adjunctive treatment for adults with
focal-onset seizures, from the Phase III clinical trials and
some substantial open, unblinded studies.
ESL pharmacology
Following oral administration, ESL is rapidly and exten-
sively metabolized by first-pass hepatic hydrolysis to esli-
carbazepine (S-licarbazepine), the active metabolite
responsible for its pharmacological effect [19]. Eslicar-
bazepine accounts for approximately 94% of plasma drug
exposure following oral administration of ESL, other
moieties being R-licarbazepine (*5%) and oxcarbazepine
(OXC; \1%) [20]. Eslicarbazepine displays linear phar-
macokinetics at clinically relevant ESL doses and its
effective half-life is 20–24 h [21].
ESL is a member of the dibenzazepine family of
AEDs, which also includes OXC and carbamazepine
(CBZ) [22]. ESL shares with OXC and CBZ the
dibenzazepine nucleus bearing the 5-carboxamide sub-
stitute, but is structurally different from these agents at
the 10,11-position [21, 23], resulting in differences in
pharmacokinetics, pharmacodynamics, and metabolism
[24]. Whereas ESL is stereoselectively metabolized pri-
marily to eslicarbazepine, OXC is metabolized to both
eslicarbazepine and R-licarbazepine, as well as being
detectable in serum as the parent compound [20].
Although exposure to eslicarbazepine, assessed as area
under the time–concentration curve (AUC), is similar fol-
lowing administration of OXC 600 mg twice daily and ESL
1200 mg OD (OXC/ESL ratio for AUC: 97% for plasma
and 112% for cerebrospinal fluid [CSF]), exposure to R-li-
carbazepine is higher for OXC than for ESL (OXC/ESL
ratio for AUC: 417% for plasma and 407% for CSF), as is
exposure to oxcarbazepine (OXC/ESL ratio for AUC: 411%
for plasma and 327% for CSF) [20]. ESL’s stereoselective
metabolism, therefore, avoids the early peak in OXC con-
centration observed in plasma and CSF following immedi-
ate-release OXC administration (Fig. 1), which correlates
with OXC-related adverse events (AEs; e.g., dizziness,
headache) [20]. This difference may explain the finding
from clinical trials that ESL is associated with fewer neu-
rological AEs than immediate-release OXC [25]. Moreover,
a retrospective, single-center study of 21 patients demon-
strated that patients switched overnight from immediate-re-
lease OXC to ESL showed improved tolerability, as
assessed using the Adverse Events Profile questionnaire
[26]. ESL also potentially differs from CBZ in terms of its
tolerability profile, since CBZ metabolism is associated with
the generation of toxic metabolites, whereas ESL metabo-
lism is not [27, 28]. Furthermore, CBZ is a potent enzyme
inducer, reducing the duration and action of many drugs
[29], and this contributes to the development of comor-
bidities such as osteoporosis, sexual dysfunction, and vas-
cular disease [29, 30]. Eslicarbazepine, the main active
metabolite of ESL after oral administration in humans, is a
weak inducer of cytochrome P450 3A4 and uridine 50-
diphospho-glucuronosyl transferases [1], but it is a less
potent enzyme inducer than CBZ. It should be noted that,
since eslicarbazepine decreases exposure to the oral con-
traceptives, levonorgestrel and ethinylestradiol, most likely
due to induction of cytochrome P450 3A4, women of
childbearing potential should use adequate contraception
during ESL treatment and up to the end of the current
menstruation cycle after treatment has been discontinued [1].
It is thought that eslicarbazepine acts primarily by
reducing the availability of voltage-gated sodium channels
(VGSCs) through enhancement of slow inactivation [31],
and, therefore, differs from CBZ, which acts by altering the
fast inactivation of VGSCs [31]. Eslicarbazepine’s appar-
ent affinity for VGSCs in the inactivated state is approxi-
mately two-fold less than that of CBZ [32] and its apparent
affinity for VGSCs in the resting state is 5- to 15-fold lower
than those of CBZ, OXC, and (R)-licarbazepine [19].
Eslicarbazepine, therefore, appears to have enhanced
inhibitory selectivity for rapidly firing ‘epileptic’ neurons
over those with normal activity [19, 33, 34]. The clinical
significance of these differences is currently not known, but
they could potentially play a role in the observed efficacy
of ESL in the presence of CBZ resistance [35, 36].
Experiments using patch-clamp recording in human and rat
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hippocampal slices have demonstrated that eslicarbazepine
exhibits maintained use-dependent blocking effects, with
significant add-on effects to CBZ in human epilepsy [36].
These findings are supported by ESL clinical trial data
demonstrating that ESL may be effective in patients whose
seizures are uncontrolled by CBZ [3–6, 37]. Eslicar-
bazepine also differs from CBZ and R-licarbazepine in its
effects on CaV3.2 inward currents, sub-maximal GABA
currents, KV7.2 outward currents, and glycine GlyRa3
receptor-mediated inward currents [34]. Although the
potential clinical significance of these differences is also
not yet known, ESL has been shown to exhibit strong
antiepileptogenic effects in experimental models of epi-
lepsy that may in part be due to its inhibitory effects on
CaV3.2 T-type Ca
2? channels [36].
ESL Phase III clinical trial data
Data from randomized, double-blind,
placebo-controlled, Phase III trials
The efficacy and safety/tolerability of ESL as adjunctive
therapy in adults with focal-onset seizures have been
investigated in four international, multicenter, Phase III
trials: Studies 301 [3], 302 [4], 303 [5], and 304 [6]. All of
these individual Phase III trials met their primary end-
points. The results of a post hoc analysis of pooled data
from the randomized, double-blind, placebo-controlled
periods of Studies 301, 302, and 303 will be presented here
[38]. Subsequent findings from Study 304 [6] and a post
hoc pooled analysis of Studies 301, 302, and 304 [39–41]
are consistent with the findings of the pooled analysis of
Studies 301, 302, and 303 outlined below. ESL was
licensed as an adjunctive treatment for focal-onset seizures
by the European Medicines Agency on the basis of Studies
301, 302, and 303 [1], and by the United States Food and
Drug Administration on the basis of Studies 301, 302, and
304 [2].
Summary of pooled analysis of studies 301, 302, and 303
The trials included patients aged C18 years with a docu-
mented diagnosis of epilepsy and at least a 12-month history
of simple or complex focal-onset seizures, with or without
secondary generalization [38]. Patients were also required to
be treated with stable doses of one or two AEDs (one to three
AEDs in Study 302). The predefined key efficacy endpoints
for the pooled analysis were seizure frequency during the
12-week maintenance period (adjusted per 4 weeks), rela-
tive reduction from baseline in seizure frequency, and
responder rate (response defined asC50% seizure frequency
reduction from baseline). These endpoints were assessed for
the intention-to-treat (ITT) and per protocol (PP) popula-
tions. Safety assessments included treatment-emergent AEs
(TEAEs), clinical laboratory parameters, vital signs, and
electrocardiography (ECG) [38].
Data obtained from 1049 patients enrolled at 125 centers
in 23 countries were pooled and analyzed [38]. The majority
of the population was Caucasian and approximately 50% of
patients were males. The mean age was approximately
37 years and the mean duration of epilepsy was 22 years.
Compared with placebo, there was a statistically significant
reduction in seizure frequency during the maintenance
a b
Fig. 1 Plasma (a) and CSF (b) concentration–time profiles of OXC
following the last dose of a repeated-dose regimen of once-daily ESL
1200 mg and twice-daily OXC 600 mg to healthy volunteers (n = 7
in each group for plasma profile; n = 6 in each group for CSF
profile). CSF cerebrospinal fluid, ESL eslicarbazepine acetate, OXC
oxcarbazepine. Adapted from Nunes et al. [20] with permission from
John Wiley and Sons
J Neurol (2017) 264:421–431 423
123
period with ESL 800 mg/day and ESL 1200 mg/day in both
the ITT and PP populations (p\ 0.0001; Fig. 2a). The
median relative reduction in seizure frequency was 35% with
ESL 800 mg/day and 39% with ESL 1200 mg/day, com-
pared with 15% with placebo (ITT population). Similarly,
the responder rate was significantly higher for ESL
800 mg/day (36%) and ESL 1200 mg/day (44%), compared
with placebo (22%) (p = 0.0001 and p\ 0.0001, respec-
tively; ITT population; Fig. 2b) [38].
The incidence of TEAEs was higher for ESL than for
placebo and increased with ESL dose (Table 1) [38]. The
majority of TEAEs were of mild or moderate intensity. The
most frequently reported TEAEs (C10% of patients in any
treatment group) were dizziness, somnolence, headache,
and nausea (Table 1). Differences in the frequencies of
TEAEs between the ESL and placebo groups were mainly
observed during the first 6 weeks of treatment, after which
the frequencies across groups were similar. TEAEs leading
to discontinuation were also dose-related (Table 1); these
were mainly vertigo, diplopia, blurred vision, nausea and
vomiting, fatigue, abnormal coordination, dizziness, head-
ache, and somnolence. No dose-dependent trend was
observed for serious TEAEs. Only one patient died during
the study (placebo group). Changes in mean clinical lab-
oratory parameters did not yield clinically relevant findings
and there were no changes in vital signs or body weight of
clinical concern. Hyponatremia\125 mM was reported in
four patients [ESL 400 mg/day, n = 1 (0.5%); ESL
800 mg/day, n = 2 (0.7%); ESL 1200 mg/day, n = 1
(0.4%)]. All four patients were concomitantly treated with
CBZ at C1000 mg/day and all had sodium levels
\135 mM at baseline. ESL treatment was associated with
no clinically relevant ECG findings. No clinically signifi-
cant prolongation of the QTc interval was observed in any
patient [38].
Influence of starting dose and dose titration
scheme on incidence of TEAEs
The influence of starting dose and dose titration scheme on
the incidence of TEAEs during treatment with ESL was
examined as part of the post hoc pooled analysis of Studies
301, 302, and 304 [41]. During the 2-week titration period,
there was a marked difference between the TEAE profile of
the ESL 800 mg/day ‘without-titration’ group and the ESL
800 mg/day ‘with-titration’ group, the incidence of all of
the most frequently reported TEAEs being higher without
titration than with. The greatest differences were for
dizziness (24.9 vs. 8.5%), somnolence (15.9 vs. 5.5%),
headache (10.8 vs. 4.5%), nausea (12.2 vs. 3.0%), vomiting
(7.3 vs. 1.0%), and ataxia (6.1 vs. 0.5%). Among the
treatment groups with a target dose of ESL 800 or
1200 mg/day, the frequency of the most commonly
reported TEAEs was higher for those initiated at
800 mg/day versus 400 mg/day. The frequency of TEAEs
in the ESL 800 mg/day ‘with-titration’ and ESL
1200 mg/day ‘with-titration’ groups was similar to the ESL
400 mg/day group, and not markedly different from pla-
cebo. The incidence of rash did not appear to be related to
ESL starting dose or to the rate of dose escalation, but was
higher among patients maintained on ESL 1200 mg/day
(2.6–4.9%) than among patients maintained on ESL
a
b
Fig. 2 Efficacy analysis of pooled data from Phase III Studies 301,
302, and 303: a relative reduction from baseline in seizure frequency
during 12-week maintenance treatment with adjunctive ESL (ITT
population) and b responder rate during 12-week maintenance
treatment with adjunctive ESL (ITT population) [38] reprinted with
permission from John Wiley and Sons. Response was defined as
C50% reduction from baseline in seizure frequency; p-values refer to
comparison vs. placebo. CI confidence interval, ESL eslicarbazepine
acetate, ITT intention-to-treat, LS least squares
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800 mg/day (0.0–1.9%), ESL 400 mg/day (0.5%), or pla-
cebo (0.9%) [41].
Overall, these Phase III randomized, controlled trial data
demonstrated that ESL was effective and well tolerated as
an adjunctive therapy for adults with focal-onset seizures
[3–6, 38–41]. ESL led to dose-related improvements in
most efficacy outcomes, the effective dose range being
800–1200 mg OD [38]. The overall incidence of TEAEs
was higher at higher doses of ESL, which appears
attributable to expected AEs, such as diplopia, dizziness,
headache, vertigo, and somnolence. The incidence of seri-
ous TEAEs in these studies was low. TEAEs were generally
predictable, manageable, occurred during the early stages of
treatment, and were of mild to moderate intensity [38]. The
pooled analysis of Studies 301, 302, and 304 also indicated
that the frequency of TEAEs with ESL may be minimized
by use of an appropriate titration scheme [41].
Data from open-label Phase III studies
ESL safety/tolerability and efficacy in elderly patients
The safety/tolerability and efficacy of adjunctive ESL
therapy in elderly patients (aged C65 years) with focal-
onset seizures were assessed in a multicenter, open-label,
non-controlled, single-arm Phase III trial [10]. The trial
employed flexible doses of ESL (400–1200 mg OD), in
accordance with the recommendations approved by the
regulatory authority [1]. Patients were included if they had
at least two focal-onset seizures during the 8-week baseline
period and were being treated with one or two AEDs other
than OXC. After an 8-week baseline period, patients
entered a 26-week maintenance period, during which ESL
was initiated at 400 mg OD and adjusted based on indi-
vidual response (400–1200 mg/day). Safety/tolerability
was assessed by evaluation of TEAEs, clinical laboratory
evaluations, vital signs, 12-lead ECG, physical/neurologi-
cal examinations, Norris’ scales for evaluation of sedative
effects, and the Columbia Suicide Severity Rating Scale.
Efficacy was assessed as the absolute and relative change
from baseline in seizure frequency (standardized to fre-
quency per 4 weeks), responder rate (response defined as
C50% seizure frequency reduction), and seizure freedom
rate [10].
The study population comprised 72 patients (52.8%
males), with a mean age of 71.6 years (range
65–84 years) [10]. The mean treatment duration was
151.8 days and the mean ESL dose during the overall
treatment period was 591.9 mg/day. The majority of
patients received doses no higher than 800 mg/day. The
most frequently reported TEAEs (C5% patients) were
dizziness (12.5%), somnolence (9.7%), fatigue (8.3%),
convulsion (8.3%), hyponatremia (8.3%), nasopharyngitis
(6.9%), and upper respiratory tract infection (5.6%). The
majority of TEAEs were of mild or moderate intensity. In
total, 16 serious TEAEs were reported for ten (13.9%)
patients; none occurred in more than one patient. Three
patients died but none of the deaths was considered
Table 1 Summary of TEAEs in pooled analysis of Studies 301, 302, and 303 [38]
Placebo
(n = 289)
ESL 400 mg/day
(n = 196)
ESL 800 mg/day
(n = 284)
ESL 1200 mg/day
(n = 280)
Total ESL
(n = 760)
Any TEAE, n (%) 134 (46.4) 119 (60.7) 178 (62.7) 189 (67.5) 486 (63.9)
TEAEs with incidence C10% in any
treatment group, n (%)
Dizziness 21 (7.3) 26 (13.3) 60 (21.1) 81 (28.9) 167 (22.0)
Somnolence 27 (9.3) 21 (10.7) 37 (13.0) 42 (15.0) 100 (13.2)
Headache 25 (8.7) 17 (8.7) 29 (10.2) 38 (13.6) 84 (11.1)
Nausea 6 (2.1) 10 (5.1) 21 (7.4) 28 (10.0) 59 (7.8)
TEAEs considered possibly related to ESL
treatment, n (%)
72 (24.9) 75 (38.3) 134 (47.2) 154 (55.0) 363 (47.8)
TEAEs by severity, n (%)
Mild 56 (19.4) 56 (28.6) 72 (25.4) 56 (20.0) 184 (24.2)
Moderate 65 (22.5) 45 (23.0) 82 (28.9) 101 (36.1) 228 (30.0)
Severe 13 (4.5) 18 (9.2) 24 (8.5) 32 (11.4) 74 (9.7)
TEAEs leading to discontinuation, n (%) 13 (4.5) 17 (8.7) 33 (11.6) 54 (19.3) 104 (13.7)
Any serious TEAE, n (%) 4 (1.4) 9 (4.6) 10 (3.5) 9 (3.2) 28 (3.7)
Deaths, n (%) 1 (0.3) 0 0 0 0
ESL eslicarbazepine acetate, TEAE treatment-emergent adverse event
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related to study medication. Sixteen (22.2%) patients
discontinued due to TEAEs. TEAEs leading to discon-
tinuation of more than one patient were hyponatremia
(n = 3), dizziness (n = 2), and fatigue (n = 2). Labora-
tory-related TEAEs affecting more than one patient were
hyponatremia (8.3%), increased blood creatine phospho-
kinase (4.2%), and increased gamma-glutamyltransferase
(4.2%). For vital signs, ECG, and physical and neuro-
logical examinations, no trends were observed and the
incidence of relevant findings was low. The Norris’
adapted mental sedation scales showed minor changes in
patient responses towards a slight worsening of mean
values. There were no reports of suicidality post baseline,
as assessed by the Columbia Suicide Severity Rating
Scale and TEAE reporting [10].
For the full analysis set (n = 71), the responder and sei-
zure freedom rates during the maintenance period were 54.9
and 15.5%, respectively [10]. The corresponding values for
the PP set (n = 55) were 56.4 and 12.7%, respectively. The
mean (standard deviation) standardized seizure frequency
decreased from 4.8 (5.5) during the 8-week baseline period to
3.6 (5.8) during the 26-week maintenance period (full anal-
ysis set). Overall, the study found that adjunctive treatment
with ESL (400–1200 mg OD) in elderly patients with focal-
onset seizures was efficacious and did not raise any unex-
pected safety concerns [10].
Impact of ESL on QoL
During the 1-year, open-label extension studies of the
Phase III adjunctive therapy trials, patients were treated
with flexible ESL dosing (400–1200 mg/day) according to
response and tolerability [7–9]. These studies included an
assessment of the long-term impact of adjunctive ESL
treatment on health-related QoL, by employing the Quality
of Life in Epilepsy Inventory-31 (QOLIE-31) questionnaire
[42] at baseline of the initial Phase III trial and at the end of
1-year open-label treatment or at early discontinuation
[7, 8, 18]. In the open-label extension of Study 301,
QOLIE-31 scores increased (i.e., improved) from baseline
to the last assessment and the improvement was statisti-
cally significant for all subscales except emotional well-
being [7]. The mean relative improvement in QOLIE-31
subscale scores ranged from 7.1 (emotional well-being) to
51.4 (seizure worry), and the overall mean score improved
from 54.8 at baseline to 58.3 at the last assessment
(p\ 0.0001) [7]. Similar improvements in QOLIE-31
scores were observed in the open-label extensions of Study
302 (significant improvements in the overall QoL, seizure
worry, and medication effects subscales and overall score)
[8] and Study 303 (significant improvements in all sub-
scales and overall score) [18].
Phase IV open study data
EPOS study
The Eslicarbazepine acetate in Partial-Onset Seizures
(EPOS) study was a prospective, non-interventional, open-
label investigation conducted in 88 sites across eight
European countries [13]. Its objectives were to assess the
retention rate, seizure control, safety/tolerability and effect
on QoL of ESL as add-on to antiepileptic monotherapy in
everyday clinical practice. Adult patients with focal-onset
seizures (with or without secondary generalization),
insufficiently controlled under AED monotherapy, were
offered participation in the study if their clinician had
previously and independently decided to initiate ESL add-
on therapy. ESL was recommended to be used according to
approved guidance [1]. The primary endpoint was retention
rate after 6 months. Other assessments included retention
rate after 3 months, and efficacy, safety/tolerability, and
QoL after 3 and 6 months. Efficacy was assessed as seizure
frequency during the previous 3 months, responder rate
(response defined as C50% seizure frequency reduction
from baseline), and seizure freedom rate (seizure freedom
defined as no seizures within the previous 3 months).
Safety/tolerability was assessed by evaluating AEs and
adverse drug reactions, defined as AEs with causal rela-
tionship to study drug. QoL was assessed using the patient-
rated Quality of Life in Epilepsy Inventory-10 (QOLIE-10)
[13, 43].
A total of 219 patients were included in the study [13].
The median age was 43 years (range 18–83 years) and
57.5% were males. The mean time since epilepsy diagnosis
was 12.3 years (range 0–57.3 years). Most patients
(74.3%) received a target ESL dose of 800 mg/day. For the
majority of patients (79.3%), the target dose was reached
with one titration step. The most commonly used baseline
AED monotherapies (C5% of patients) were levetiracetam
(37.9%), lamotrigine (24.7%), valproate (13.7%), and
carbamazepine (6.4%). The 6-month retention rate was
82.2% [95% confidence interval (CI) 76.5–87.0%] and the
3-month retention rate was 89.0% (95% CI: 84.1–92.9%).
After 3 and 6 months, responder rates were 69.9 and
81.8%, respectively, and seizure freedom rates were 25.9
and 39.2%, respectively (Fig. 3). AEs were reported for
26.0% of patients and adverse drug reactions for 22.4% of
patients. Eight patients (3.7%) experienced serious AEs.
No AE was reported for [5% of patients. The most fre-
quently reported AEs were dizziness (4.6%), headache
(3.2%), convulsion (3.2%), and fatigue (2.7%). The mean
QOLIE-10 score decreased (i.e., improved) from 2.9
(n = 128) at baseline to 2.4 (n = 114) after 3 months and
2.1 (n = 109) after 6 months [13].
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Post hoc subgroup analyses were conducted for those
45 patients in EPOS who had documented non-response to
historic CBZ treatment [44] and the 41 patients aged
[60 years [45]. Efficacy, safety/tolerability, and the impact
of treatment on QoL were assessed as for the overall
population [13]. In the subgroup of patients who had pre-
viously not responded to CBZ treatment, the retention,
responder, and seizure freedom rates after 6 months were
88.9% (95% CI: 75.9–96.3%), 95.1% (95% CI:
83.5–99.4%), and 33.3% (95% CI: 19.6–49.5%), respec-
tively, and the mean QOLIE-10 score decreased from 2.8
(n = 21) at baseline to 2.2 (-13.0%; n = 18) after
6 months [44]. Two AEs were reported for two (4.4%)
patients and both were hyponatremia [44]. Similarly, for
the elderly patients included in EPOS, the retention,
responder, and seizure freedom rates after 6 months were
78.0% (95% CI: 62.4–89.4%), 83.3% (95% CI:
65.3–94.4%), and 56.3% (95% CI: 37.7–73.6%), respec-
tively, and the mean QOLIE-10 score decreased from 2.7
(n = 28) at baseline to 2.2 (-14.5%; n = 24) after
6 months [45]. Twelve AEs were reported for six (14.6%)
patients and no AE was reported in[5% of patients. The
most frequently reported AEs were dizziness (4.9%) and
allergic dermatitis (4.9%) [45].
Overall, the EPOS study demonstrated that ESL as add-
on to antiepileptic monotherapy was associated with
favorable retention and seizure control, and was well tol-
erated by the majority of adult patients [13]. ESL treatment
also resulted in improvements in patient-rated QoL [13] in
patients who were less severely ill at baseline than those
enrolled in clinical trials. Moreover, ESL was shown to be
effective and generally well tolerated when used in elderly
patients, and in those who had previously not responded to
CBZ therapy [44, 45].
Spanish ESLIBASE study
The ESLIBASE study was a multicenter, retrospective,
non-interventional study undertaken to evaluate the long-
term efficacy and safety of adjunctive ESL therapy in
patients with focal epilepsy in a clinical practice setting
[14]. Conducted in 12 hospitals in Spain, the study inclu-
ded patients with a diagnosis of epilepsy and focal-onset
seizures who were treated with ESL according to clinical
practice and whose ESL treatment was initiated between
January 2010 and July 2012. Data were collected retro-
spectively at baseline and at 3, 6, and 12 months. Efficacy
assessments included responder rate (response defined as
C50% seizure frequency reduction from baseline), seizure
freedom rate, and retention rate, all assessed after 3, 6, and
12 months. Safety assessments included evaluation of AEs
[14].
The study population comprised 327 patients (52.0%
female) with a mean age of 41.9 years (range 14–87 years)
[14]. For most patients, ESL was initiated at 400 mg/day as
a single dose and up-titrated in 400-mg increments every 7,
10, or 14 days until the optimal dose was reached. The
maximal approved dose (1200 mg/day) was exceeded if
deemed necessary; 26 (7.9%) patients were taking doses
[1200 mg/day at last observation. The median ESL dose
at Months 3, 6, and 12 was 800, 1200, and 1200 mg/day,
respectively (Villanueva, personal communication), with
doses ranging from 400 to 2000 mg/day at every timepoint.
There was a significant decrease in mean number of con-
comitant AEDs used from baseline (2.0) to last follow-up
(1.6; p\ 0.001) [14].
Retention rates after 3, 6, and 12 months were 89.3,
80.1, and 72.5%, respectively [14]. After 12 months,
52.5% of patients were responders and 25.3% of patients
were seizure free (Fig. 4). The cumulative rate of AEs that
were possibly related to ESL treatment was 40.7% at
12 months. The most commonly reported TEAEs (C5% of
patients) were dizziness/nausea (11.3%), somnolence
(6.1%), and ataxia (5.1%). Rash/pruritus was reported for
12 (3.6%) patients and hyponatremia (ranging from
116–128 mEq/L) was reported for nine (2.7%) patients.
The majority of AEs were mild or moderate in intensity.
The cumulative rate of AEs leading to treatment discon-
tinuation was 16.2% after 12 months. Of 26 patients who
were transitioned from OXC to ESL due to OXC-related
AEs, 15 (57.7%) no longer had AEs after transitioning to
ESL. Similarly, of 17 patients who were transitioned from
CBZ to ESL due to CBZ-related AEs, eight (47.1%) no
longer had AEs after transitioning to ESL [14].
Fig. 3 Responder and seizure freedom rates after 3 and 6 months in
the EPOS study. Response was defined as C50% seizure frequency
reduction in the previous 3 months, compared with the 3 months prior
to initiating ESL therapy. Seizure freedom is presented for total
seizures and by seizure type. n = 212 at 3 months; n = 189 at
6 months [13] reprinted with permission from John Wiley and Sons
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Other open studies
A retrospective, consecutive, 2-year observational study
assessed the efficacy and tolerability of adjunctive ESL
therapy in 152 patients (mean age 38.5 years; eight patients
\18 years) treated at a single center in Portugal [15].
Patients’ mean epilepsy duration was 26.8 years and their
mean seizure frequency in the 3 months prior to ESL initi-
ation was 19.7 seizures/month. Kaplan–Meier retention rates
were 82.9, 71.3, 65.1, and 62.8% at 6, 12, 18, and 24 months,
respectively. Retention was shown to be unaffected by
gender, diagnosis, age, or epilepsy duration. Overall, 56
patients (36.8%) discontinued ESL treatment: 32 (57.1%)
due to AEs, 19 (33.9%) due to lack of efficacy, and five
(8.9%) due to other reasons. Responder rates at 6, 12, 18, and
24 months were 25.7, 25.7, 19.0, and 17.1%, respectively.
AEs were reported by 64 patients (42.1%), half of whom
discontinued ESL therapy due to AEs. The most frequently
reported AEs were dizziness and somnolence/slowness. AEs
were more frequently reported in treatment regimens that
included CBZ. Overall, no new safety signals emerged
compared with evidence from ESL clinical trials [15].
An observational, descriptive, cross-sectional study was
conducted to assess efficacy and tolerability in the first 61
patients to receive adjunctive ESL therapy for drug-resis-
tant epilepsy at a single epilepsy unit in Spain [16]. The
mean follow-up duration was 4.7 ± 3.2 months and the
retention rate at 3 months was 75.4%. In 40 patients with a
minimum follow-up period of 3 months, monthly median
seizure frequency decreased from baseline by 63.6%
(p\ 0.001); 12 patients (30.0%) achieved a reduction of
C80%, and five (12.5%) achieved seizure freedom. AEs
were reported by 35 patients (57.4%) and mostly occurred
during titration. The most commonly reported AE was
dizziness (34.4%). Two patients experienced exanthematic
cutaneous reactions and four patients (6.6%) developed
hyponatremia (sodium range 128–132 mmol/L). There
were no sodium values \125 mmol/L and no patients
discontinued ESL due to low sodium levels. Twelve
patients (19.7%) switched overnight to ESL from OXC,
using a dose ratio of 1:1, and 13 patients (21.3%) switched
overnight from CBZ to ESL, using a dose ratio of 1:1.3.
Switching from OXC to ESL was found to be effective and
well tolerated, whereas switching from CBZ to ESL was
less effective and less well tolerated [16].
In another audit of 105 patients treated with ESL at a
single unit in Spain, 20.7% of patients remained seizure-free
and 58.4% demonstrated[50% seizure frequency reduction
after the introduction of ESL [17]. After 6 months, 18.1% of
patients had experienced AEs (the most common being
cognitive disorders) and 11.5% had discontinued treatment.
The addition of ESL to lacosamide was shown to be signif-
icantly less effective in controlling seizures than its addition
to other AEDs, whereas the addition of ESL to other sodium
channel blockers was shown to be similar in efficacy to its
addition to other AEDs [17].
Discussion
The clinical efficacy and safety/tolerability of adjunctive
ESL therapy in adults with focal-onset seizures have been
established in a program of randomized, double-blind,
placebo-controlled, Phase III trials [3–6]. These trials have
also established the effectiveness of adjunctive ESL ther-
apy by including patient-reported outcome measures that
have demonstrated improvements in health-related QoL
over the long term [7, 8, 18]. ESL has additionally been
shown to be well tolerated and efficacious when used in the
adjunctive setting in elderly patients with focal-onset sei-
zures [10].
ESL is approved in Europe at doses up to 1200 mg/day
as adjunctive therapy in adults with focal-onset seizures
[1]. Since ESL is additionally approved in the USA at
doses up to 1600 mg/day as monotherapy in adults with
uncontrolled focal-onset seizures [2], on the basis of the
findings of two Phase III conversion to monotherapy trials
[46, 47], it remains to be determined whether the
1600-mg/day dose might also be effective and well toler-
ated in the adjunctive setting.
There has been increasing acknowledgement of the
importance of open studies in helping to inform health
policy decisions, and bodies such as the International
Society for Pharmacoeconomics and Outcomes Research
have highlighted the need for rigor and transparency when
conducting such studies [48, 49]. In the case of ESL,
Fig. 4 Responder and seizure freedom rates after 3, 6, and 12 months
of ESL treatment in the ESLIBASE study (n = 327). Response was
defined as C50% seizure frequency reduction from baseline. Seizure
freedom was defined as no seizures from the beginning of the study
(up to timepoints earlier than the 12-month visit), no seizures for the
last 6 months (at the 12-month visit), or no seizures for 12 months if
patients were seizure free in the 3 months prior to study entry [14]
reprinted with permission from Elsevier
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clinical trial data have been supported by several open
studies, which have demonstrated that adjunctive ESL
treatment was effective and generally well tolerated as
long-term therapy in clinical practice [14, 15], and when
used as the only add-on to AED monotherapy in clinical
practice [13]. The effectiveness of adjunctive ESL treat-
ment in clinical practice was associated with favorable
retention and improvements in health-related QoL [13, 14].
Moreover, when used as the only add-on to AED
monotherapy, ESL was shown to be efficacious and gen-
erally well tolerated in elderly patients [45] and in patients
who had previously not responded to CBZ therapy [44].
Hyponatremia and rash have been reported as common
AEs in patients treated with ESL in clinical trials (1.2 and
1.1%, respectively) [1]. Higher rates of hyponatremia have
been reported in elderly patients [10] and in some post-
marketing open studies [14, 16]. It is, therefore, good
practice to monitor for the potential development of
hyponatremia with ESL treatment through laboratory test-
ing, particularly in the elderly. Rash has also been reported
in some open studies [14, 16]. Neuropsychiatric and cog-
nitive side effects are reported uncommonly with ESL
treatment (C1/1000 to\1/100 patients), with the exception
of disturbance in attention (C1/100 to\1/10 patients) [1].
The effectiveness of ESL in patients who are resistant to
CBZ therapy may be due to differences between the agents in
terms of their modes of action [31, 36]. Moreover, given the
pharmacological differences between ESL and OXC and
CBZ [21, 23, 24], there may be other clinical situations in
which it is appropriate to consider transitioning patients from
CBZ or OXC to ESL [50]. When transitioning patients from
OXC to ESL, a dose ratio of 1:1 is recommended and it has
been claimed that the change is possible to undertake in a
single step, with no adjustment to comedication required
[50]. The transitioning of patients from CBZ to ESL is less
straightforward and should be carefully considered on a
case-by-case basis, taking account of the patient’s clinical
characteristics and comedications, which may require dose
adjustment due to CBZ being a strong inducer of CYP
enzymes [50]. In general, a CBZ:ESL dose ratio of 1:1.3
should be used and patients should be transitioned over a
minimum period of 1–2 weeks [50] although longer periods
of switching are often advised. In addition to patients who are
resistant to CBZ therapy, clinical situations in which it might
be appropriate to consider a transition to ESL include
patients who experience OXC- or CBZ-related AEs (e.g.,
cognitive AEs) and those who experience, or are at risk of
developing, metabolic problems resulting from CBZ
induction of enzymes involved in endogenous metabolic
pathways (e.g., hypercholesterolemia, osteoporosis, sexual
dysfunction) [50]. It should be noted, however, that long-
term follow-up studies are required to confirm whether ESL
can reduce the risk of the types of long-term metabolic
sequelae reported for CBZ or not. Other patients for whom it
might be appropriate to consider transitioning from CBZ or
OXC to ESL are those who are poorly compliant with two- or
three-times daily dosing [50].
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